Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors

Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors

Introduction: Clinical roles of plasma IL-6 levels have been reported in patients with various cancers, including non-small cell lung cancer (NSCLC), treated with immune checkpoint inhibitors (ICIs). However, the roles of other IL-6 signaling components, soluble IL-6 receptor (sIL-6R) and soluble gp...

Full description

Bibliographic Details
Main Authors: Yoshiro Nakahara, Taku Kouro, Satoru Motoyama, Masatomo Miura, Kazuma Fujita, Yuka Igarashi, Naoko Higashijima, Norikazu Matsuo, Hidetomo Himuro, Feifei Wei, Shun Horaguchi, Kayoko Tsuji, Yasunobu Mano, Mitsuru Komahashi, Haruhiro Saito, Koichi Azuma, Tetsuro Sasada
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
immune checkpoint inhibitor
non-small cell lung cancer (NSCLC)
IL-6
soluble IL-6 receptor (sIL-6R)
soluble glycoprotein 130 (sgp130)
PD-1
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2023.1324898/full

Similar Items

Similar Items